Skip to main content

CareTalk Blog

Cascade Health Alliance Blog Home

Early Periodic Screening Diagnosis Treatment (EPSDT)

Effective January 1, 2023, Oregon will implement the full Early and Periodic Screening, Diagnosis and Treatment benefit (EPSDT) for children and youth until their 21st birthday.

Importance of the Annual Wellness Visit (AWV)

Annual Wellness Visits (AWVs) are a great opportunity for patients to connect with their provider about health and wellness during a covered visit. This high-value health action enables providers to establish a personal connection with the patient/member and opens the lines of communication essential for long-term health and the preventive measures that support it.

CHA Clinical Guidelines

All Medicaid organizations, including CHA, are required to adopt, disseminate, and apply clinical practice guidelines according to federal regulations.

Prioritized Population

The goal of this program is to ensure that the most vulnerable individuals in our community are screened for social and healthcare needs, as well as provided the necessary assistance in meeting their health care goals. These groups are identified as the State’s “Prioritized Population”.

Formulary Change

CHA is pleased to be able to remove prior authorization requirements for a number of commonly used medication. This will help to reduce the administrative burden for all and streamline care.

Traditional Healthcare Workers: Birthing Doulas

In partnership with the Oregon Health Authority, CHA is growing our local network of certified Doulas in Klamath County.

What You Need to Know About Beating Diabetes

There are two types of diabetes – Type 1 and Type 2. Understand the two and learn how to beat diabetes.

Initiation and Engagement in Treatment

For the 2021 measurement year, the OHA has introduced a new incentive metric: Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment, or IET.



Have you heard of the new insulin aiming to be deemed “biosimilar” to insulin glargine (basal insulin) by the FDA at a price point that is approximately 65% less than Lantus and 50% below the current price of Basaglar?